Last reviewed · How we verify
Lampit (NIFURTIMOX)
Lampit works by releasing reactive oxygen species that damage the DNA of Trypanosoma cruzi, ultimately killing the parasite.
At a glance
| Generic name | NIFURTIMOX |
|---|---|
| Sponsor | Bayer |
| Drug class | nifurtimox |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
| First approval | 2020 |
Mechanism of action
Nifurtimox is an antiprotozoal drug [see Microbiology (12.4)].
Approved indications
- Infection by Trypanosoma cruzi
Common side effects
- Vomiting
- Abdominal pain
- Diarrhea
- Headache
- Decreased appetite
- Pyrexia
- Weight decreased
- Eosinophilia
- Dizziness
- Rash
- Urticaria
- Anemia
Key clinical trials
- An Observational Pregnancy Safety Study in Women Who Were Exposed to the Drug Nifurtimox During Pregnancy to Learn About the Risk of Pregnancy Complications and About the Mother's and Baby's Health
- A Study to Learn How Well Nifurtimox Works and How Safe it is in Children Aged 0 to 17 Years With Chagas' Disease, an Inflammatory, Infectious Disease Caused by the Parasite Trypanosoma Cruzi (PHASE3)
- Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma (PHASE2)
- New Therapies and Biomarkers for Chagas Infection (PHASE2)
- Nifurtimox Versus Benznidazole Effectiveness and Tolerance for Chagas Disease Treatment
- Study on Benefits of Therapy With Nifurtimox in Chagas Disease, a Parasitic Illness Mostly Transmitted to Humans by a Bug, Using Information From Patient Medical Records in Argentina
- Study to Assess the Food Effect on the Pharmacokinetics of Nifurtimox Tablets in Chronic Chagas' Patients - Dietary Habits Study (PHASE1)
- Study to Assess Bioequivalence of a New Nifurtimox Oral Tablet Formulation (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lampit CI brief — competitive landscape report
- Lampit updates RSS · CI watch RSS
- Bayer portfolio CI